Stock screenerAll disclosures → EDGAR →
ABVX
Conviction 39HealthcareScan · Thu, Sep 24, 2026Abivax S.A. (ABVX) closed at $94.89 (+0.81%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 30, RS Rating 82, -34.7% from its 52-week high, -29.1% year to date. Sector: Healthcare · Biotechnology.
ABVX$94.89+0.81%
ResistanceSupportVol 14Vol MA14 1.47M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price94.89
Change+0.81%
Gap-1.23%
Rel volume1.69×
Avg volume1.33M
Avg $ vol142.75M
SMA 20109.56
SMA 50118.77
SMA 200118.68
Price vs 50-20.11%
Price vs 200-20.04%
MA stackmixed
50/200 cross—
Supertrenddown · 108.48
RSI (14)30
MACD hist-1.66
MACD crossbear · 7d
Stoch %K / %D10 / 7
ADX (14)31
+DI / −DI9 / 38
RSI divergence—
MACD divergenceBullish
ATR %5.11%
ADR %4.07%
52w high145.31
52w low72.50
From 52w high-34.70%
Above 52w low+30.88%
New 52w highNo
SqueezeOff
Bollinger width27.57%
%B0.01
Donchian pos10.22%
Donchian high120.63
Donchian low91.96
AVWAP (52w high)114.81
vs AVWAP high-17.35%
AVWAP (52w low)109.07
vs AVWAP low-13.00%
OBV trendDown
Chaikin MF (20)-0.20
Today vs 20d1.69×
Avg vol (14d)1.47M
Avg vol (20d)1.33M
Avg $ vol (20d)142.75M
Market cap7.45B
RS Rating82 / 99
RS 3m (vs SPY)-1.76%
RS 6m (vs SPY)-31.10%
RS line new highNo
Trend template1/8
Technical rank14.5
1 week-11.31%
1 month-19.54%
3 months+2.73%
6 months-14.28%
1 year+15.69%
YTD-29.06%
P/E—
P/B—
P/S—
P/FCF—
EPS—
Div yield—
ROE—
ROA—
Debt/Eq—
Current—
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth—
Price target160.30
Target upside68.93%
Analyst ratingBuy
Institutional63.93%
Ent. value7.45B
Revenue—
Net income—
Gross profit—
Free cash flow—
IndustryBiotechnology
ExchangeNasdaq
Shares out79.77M
Employees69
ListedFri, Oct 20, 2023
Free float69.03M
Float %79.1%
Short interest6.96M
Days to cover8.0d
Short volume37.1%
Squeeze score55 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$1.71 vs −$1.08
Last surprise-58.3% miss
Setup gradeD
Conviction39 / 100
Pattern quality—
Tech rank14.5 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance127.49
Support105.75
Days since event—
Candle confirm—
Recent news
- Abivax (NASDAQ:ABVX) Shares Down 3.4% Following Weak Earningsmarketbeat.com · Tue, Sep 22, 2026
- These Analysts Slash Their Forecasts On Abivax Following H1 ResultsBenzinga · Tue, Sep 22, 2026
- Abivax (NASDAQ:ABVX) Given New $118.00 Price Target at WedbushMarketBeat · Tue, Sep 22, 2026
- Barclays Reaffirms Overweight Rating for Abivax (NASDAQ:ABVX)MarketBeat · Tue, Sep 22, 2026
- Abivax (NASDAQ:ABVX) Releases Earnings Results, Misses Estimates By $0.70 EPSMarketBeat · Mon, Sep 21, 2026
- Abivax (ABVX) raises €767M as lead colitis drug targets Q4 2026 FDA filingStock Titan · Mon, Sep 21, 2026
- Abivax Presents Business Updates and First Half 2026 Financial ResultsYahoo Finance · Mon, Sep 21, 2026
- Abivax S.A.: 6-K filedSEC EDGAR · Mon, Sep 21, 2026
- Abivax SA (ABVX) JUN/2026 Earning PredictionIntellectia AI · Mon, Sep 21, 2026
- ABVX Tanks 30% After-Hours Despite 51% Remission In Ulcerative Colitis Trial — Rare Cancer Concerns Hit SentimentStocktwits · Sun, Sep 20, 2026
Congress activity
Disclosed STOCK Act trades in ABVX
No recent disclosed trades by Congress in ABVX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in ABVX
No recent insider (Form 4) filings in ABVX. Insiders must file within two business days of a trade.
SEC filings
EDGAR filings in ABVX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.